Table 4 Outcomes of STEMI and NSTEMI patients in 30-day follow-up
From: Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic
| Â | STEMI | NSTEMI | ||||
|---|---|---|---|---|---|---|
Group 1 (n = 153) | Group 2 (n = 81) | p-value | Group 1 (n = 101) | Group 2 (n = 43) | p-value | |
All-cause mortality, n (%) | 5 (3.3) | 6 (7.4) | 0.363 | 3 (3.0) | 8 (18.6) |  < 0.003* |
MACE, n (%) | 9 (5.9%) | 8 (9.9%) | 0.534 | 5 (5.0%) | 8 (18.6%) | 0.020* |
 All-cause death | 5 (3.3) | 6 (7.4) | 0.363 | 3 (3.0) | 8 (18.6) |  < 0.003* |
 Recurrent AMI | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
 Heart failure | 1 (0.7) | 2 (2.6) | 0.580 | 0 (0.0) | 0 (0.0) | – |
 Revascularization | 3 (2.1) | 0 (0.0) | 0.502 | 2 (2.2) | 0 (0.0) | 0.910 |
 Stroke | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |